The quest for host targets to combat dengue virus infections

Current Opinion in Virology

Volumn 20, Issue , 2016, Pages 47-54

  Acosta, Eliana G ^a   Bartenschlager, Ralf ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Partner Site Heidelberg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HOST FACTOR; PROTEASOME; UBIQUITIN; VIRUS FUSION INHIBITOR;

ANTIVIRAL THERAPY; CELL ADHESION; DENGUE; ENDOCYTOSIS; HUMAN; LIPID METABOLISM; MEMBRANE FUSION; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; REVIEW; UNFOLDED PROTEIN RESPONSE; VIRION; VIRUS ENTRY; VIRUS MORPHOGENESIS; VIRUS REPLICATION; DENGUE VIRUS; DRUG DEVELOPMENT; HOST PATHOGEN INTERACTION; ISOLATION AND PURIFICATION; PATHOGENICITY; PROCEDURES;

ANTIVIRAL AGENTS; DENGUE VIRUS; DRUG DISCOVERY; HOST-PATHOGEN INTERACTIONS; HUMANS;

EID: 84987916117     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2016.09.003     Document Type: Review

References (83)

1. 1 Bhatt, S., Gething, P.W., Brady, O.J., Messina, J.P., Farlow, A.W., Moyes, C.L., Drake, J.M., Brownstein, J.S., Hoen, A.G., Sankoh, O., et al. The global distribution and burden of dengue. Nature 496 (2013), 504–507.
2. 2 Acosta, E.G., Bartenschlager, R., Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development. Exp Rev Vaccines 15 (2016), 467–482.
3. 3 Guy, B., Jackson, N., Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol 14 (2016), 45–54.
4. 4• Lim, S.P., Wang, Q.Y., Noble, C.G., Chen, Y.L., Dong, H., Zou, B., Yokokawa, F., Nilar, S., Smith, P., Beer, D., Lescar, J., Shi, P.Y., Ten years of dengue drug discovery: progress and prospects. Antiviral Res 100 (2013), 500–519 A comprehensive review nicely adressing the problems inherent to the developental of DENV-specific antiviral drugs with a focus on DAAs.
5. 5 Acosta, E.G., Kumar, A., Bartenschlager, R., Revisiting dengue virus–host cell interaction: new insights into molecular and cellular virology. Adv Virus Res 88 (2014), 1–109.
6. 6 Perera-Lecoin, M., Meertens, L., Carnec, X., Amara, A., Flavivirus entry receptors: an update. Viruses 6 (2014), 69–88.
7. 7 Cruz-Oliveira, C., Freire, J.M., Conceicao, T.M., Higa, L.M., Castanho, M.A., Da Poian, A.T., Receptors and routes of dengue virus entry into the host cells. FEMS Microbiol Rev 39 (2015), 155–170.
8. 8 Chen, Y., Maguire, T., Hileman, R.E., Fromm, J.R., Esko, J.D., Linhardt, R.J., Marks, R.M., Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 3 (1997), 866–871.
9. 9 Okamoto, K., Kinoshita, H., Parquet, M.C., Raekiansyah, M., Kimura, D., Yui, K., Islam, M.A., Hasebe, F., Morita, K., Dengue virus strain DEN2 16681 utilizes a specific glycochain of syndecan-2 proteoglycan as a receptor. J GenVirol 93 (2012), 761–770.
10. 10 Lee, E., Pavy, M., Young, N., Freeman, C., Lobigs, M., Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses. Antiviral Res 69 (2006), 31–38.
11. 11 Talarico, L.B., Damonte, E.B., Interference in dengue virus adsorption and uncoating by carrageenans. Virology 363 (2007), 473–485.
12. 12 Pujol, C.A., Estevez, J.M., Carlucci, M.J., Ciancia, M., Cerezo, A.S., Damonte, E.B., Novel DL-galactan hybrids from the red seaweed Gymnogongrus torulosus are potent inhibitors of herpes simplex virus and dengue virus. Antivir Chem Chemother 13 (2002), 83–89.
13. 13 Ichiyama, K., Gopala Reddy, S.B., Zhang, L.F., Chin, W.X., Muschin, T., Heinig, L., Suzuki, Y., Nanjundappa, H., Yoshinaka, Y., Ryo, A., et al. Sulfated polysaccharide, curdlan sulfate, efficiently prevents entry/fusion and restricts antibody-dependent enhancement of dengue virus infection in vitro: a possible candidate for clinical application. PLoS Negl Trop Dis, 7, 2013, e2188.
14. 14 Talarico, L.B., Pujol, C.A., Zibetti, R.G., Faria, P.C., Noseda, M.D., Duarte, M.E., Damonte, E.B., The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell. Antiviral Res 66 (2005), 103–110.
15. 15 Alen, M.M., Kaptein, S.J., De, B.T., Balzarini, J., Neyts, J., Schols, D., Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection. Virology 387 (2009), 67–75.
16. 16 Alen, M.M., De, B.T., Kaptein, S.J., Balzarini, J., Neyts, J., Schols, D., Broad antiviral activity of carbohydrate-binding agents against the four serotypes of dengue virus in monocyte-derived dendritic cells. PLoS One, 6, 2011, e21658.
17. 17 Varga, N., Sutkeviciute, I., Ribeiro-Viana, R., Berzi, A., Ramdasi, R., Daghetti, A., Vettoretti, G., Amara, A., Clerici, M., Rojo, J., Fieschi, F., Bernardi, A., A multivalent inhibitor of the DC-SIGN dependent uptake of HIV-1 and Dengue virus. Biomaterials 35 (2014), 4175–4184.
18. 18 Meertens, L., Carnec, X., Lecoin, M.P., Ramdasi, R., Guivel-Benhassine, F., Lew, E., Lemke, G., Schwartz, O., Amara, A., The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry. Cell Host Microbe 12 (2012), 544–557.
19. 19 Jemielity, S., Wang, J.J., Chan, Y.K., Ahmed, A.A., Li, W., Monahan, S., Bu, X., Farzan, M., Freeman, G.J., Umetsu, D.T., Dekruyff, R.H., Choe, H., TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine. PLoS Pathog, 9, 2013, e1003232.
20. 20 Richard, A.S., Zhang, A., Park, S.J., Farzan, M., Zong, M., Choe, H., Virion-associated phosphatidylethanolamine promotes TIM1-mediated infection by Ebola, dengue, and West Nile viruses. Proc Natl Acad Sci U S A 112 (2015), 14682–14687.
21. 21 Acosta, E.G., Castilla, V., Damonte, E.B., Alternative infectious entry pathways for dengue virus serotypes into mammalian cells. Cell Microbiol 11 (2009), 1533–1549.
22. 22 Piccini, L.E., Castilla, V., Damonte, E.B., Dengue-3 virus entry into vero cells: role of clathrin-mediated endocytosis in the outcome of infection. PLoS One, 10, 2015, e0140824.
23. 23 Fernandez-Garcia, M.D., Meertens, L., Chazal, M., Hafirassou, M.L., Dejarnac, O., Zamborlini, A., Despres, P., Sauvonnet, N., Arenzana-Seisdedos, F., Jouvenet, N., Amara, A., Vaccine and wild-type strains of yellow fever virus engage distinct entry mechanisms and differentially stimulate antiviral immune responses. MBio 7 (2016), e01956–e2015.
24. 24 Kalia, M., Khasa, R., Sharma, M., Nain, M., Vrati, S., Japanese encephalitis virus infects neuronal cells through a clathrin-independent endocytic mechanism. J Virol 87 (2013), 148–162.
25. 25 Simanjuntak, Y., Liang, J.J., Lee, Y.L., Lin, Y.L., Repurposing of prochlorperazine for use against dengue virus infection. J Infect Dis 211 (2015), 394–404.
26. 26 van der Schaar, H.M., Rust, M.J., Waarts, B.L., Ende-Metselaar, H., Kuhn, R.J., Wilschut, J., Zhuang, X., Smit, J.M., Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. J Virol 81 (2007), 12019–12028.
27. 27 Navarro-Sanchez, E., Altmeyer, R., Amara, A., Schwartz, O., Fieschi, F., Virelizier, J.L., Arenzana-Seisdedos, F., Despres, P., Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep 4 (2003), 723–728.
28. 28 Randolph, V.B., Winkler, G., Stollar, V., Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology 174 (1990), 450–458.
29. 29 Farias, K.J., Machado, P.R., Muniz, J.A., Imbeloni, A.A., da Fonseca, B.A., Antiviral activity of chloroquine against dengue virus type 2 replication in Aotus monkeys. Viral Immunol 28 (2015), 161–169.
30. 30•• Tricou, V., Minh, N.N., Van, T.P., Lee, S.J., Farrar, J., Wills, B., Tran, H.T., Simmons, C.P., A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis, 4, 2010, e785 Clinical trial conducted in Vietnam to address the antiviral efficacy of chloroquine.
31. 31• Borges, M.C., Castro, L.A., Fonseca, B.A., Chloroquine use improves dengue-related symptoms. Mem Inst Oswaldo Cruz 108 (2013), 596–599 Clinical trial conducted in Brazil to address the antiviral efficacy of chloroquine.
32. 32 Paul, D., Bartenschlager, R., Flaviviridae replication organelles: Oh, what a tangled web we weave. Annu Rev Virol 2 (2015), 289–310.
33. 33 Carro, A.C., Damonte, E.B., Requirement of cholesterol in the viral envelope for dengue virus infection. Virus Res 174 (2013), 78–87.
34. 34 Merz, A., Long, G., Hiet, M.S., Brugger, B., Chlanda, P., Andre, P., Wieland, F., Krijnse-Locker, J., Bartenschlager, R., Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem 286 (2011), 3018–3032.
35. 35 Heaton, N.S., Perera, R., Berger, K.L., Khadka, S., LaCount, D.J., Kuhn, R.J., Randall, G., Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis. Proc Natl Acad Sci U S A 107 (2010), 17345–17350.
36. 36 Martinez-Gutierrez, M., Castellanos, J.E., Gallego-Gomez, J.C., Statins reduce dengue virus production via decreased virion assembly. Intervirology 54 (2011), 202–216.
37. 37 Perera, R., Riley, C., Isaac, G., Hopf-Jannasch, A.S., Moore, R.J., Weitz, K.W., Pasa-Tolic, L., Metz, T.O., Adamec, J., Kuhn, R.J., Dengue virus infection perturbs lipid homeostasis in infected mosquito cells. PLoS Pathog, 8, 2012, e1002584.
38. 38 Soto-Acosta, R., Mosso, C., Cervantes-Salazar, M., Puerta-Guardo, H., Medina, F., Favari, L., Ludert, J.E., Del Angel, R.M., The increase in cholesterol levels at early stages after dengue virus infection correlates with an augment in LDL particle uptake and HMG-CoA reductase activity. Virology 442 (2013), 132–147.
39. 39 Rothwell, C., Lebreton, A., Young, N.C., Lim, J.Y., Liu, W., Vasudevan, S., Labow, M., Gu, F., Gaither, L.A., Cholesterol biosynthesis modulation regulates dengue viral replication. Virology 389 (2009), 8–19.
40. 40 Samsa, M.M., Mondotte, J.A., Iglesias, N.G., Assuncao-Miranda, I., Barbosa-Lima, G., Da Poian, A.T., Bozza, P.T., Gamarnik, A.V., Dengue virus capsid protein usurps lipid droplets for viral particle formation. PLoS Pathog, 5, 2009, e1000632.
41. 41 Soto-Acosta, R., Bautista-Carbajal, P., Syed, G.H., Siddiqui, A., Del Angel, R.M., Nordihydroguaiaretic acid (NDGA) inhibits replication and viral morphogenesis of dengue virus. Antiviral Res 109 (2014), 132–140.
42. 42 Syed, G.H., Siddiqui, A., Effects of hypolipidemic agent nordihydroguaiaretic acid on lipid droplets and hepatitis C virus. Hepatology 54 (2011), 1936–1946.
43. 43 Poh, M.K., Shui, G., Xie, X., Shi, P.Y., Wenk, M.R., Gu, F., U18666A, an intra-cellular cholesterol transport inhibitor, inhibits dengue virus entry and replication. Antiviral Res 93 (2012), 191–198.
44. 44•• Whitehorn, J., Nguyen, C.V., Khanh, L.P., Kien, D.T., Quyen, N.T., Tran, N.T., Hang, N.T., Truong, N.T., Hue Tai, L.T., Cam Huong, N.T., et al. Lovastatin for the treatment of adult patients with dengue: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 62 (2016), 468–476 Evaluation of the antiviral efficacy of lovastatin in DENV-infected patients.
45. 45 Martinez-Gutierrez, M., Correa-Londono, L.A., Castellanos, J.E., Gallego-Gomez, J.C., Osorio, J.E., Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2. PLoS One, 9, 2014, e87412.
46. 46 Pollock, S., Nichita, N.B., Bohmer, A., Radulescu, C., Dwek, R.A., Zitzmann N, Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cells. Proc Natl Acad Sci U S A 107 (2010), 17176–17181.
47. 47 Jheng, J.R., Ho, J.Y., Horng, J.T., ER stress, autophagy, and RNA viruses. Front Microbiol, 5, 2014, 388.
48. 48 Umareddy, I., Pluquet, O., Wang, Q.Y., Vasudevan, S.G., Chevet, E., Gu, F., Dengue virus serotype infection specifies the activation of the unfolded protein response. Virol J, 4, 2007, 91.
49. 49 Pena, J., Harris, E., Dengue virus modulates the unfolded protein response in a time-dependent manner. J Biol Chem 286 (2011), 14226–14236.
50. 50 Carocci, M., Hinshaw, S.M., Rodgers, M.A., Villareal, V.A., Burri, D.J., Pilankatta, R., Maharaj, N.P., Gack, M.U., Stavale, E.J., Warfield, K.L., Yang, P.L., The bioactive lipid 4-hydroxyphenyl retinamide inhibits flavivirus replication. Antimicrob Agents Chemother 59 (2015), 85–95.
51. 51 Fraser, J.E., Watanabe, S., Wang, C., Chan, W.K., Maher, B., Lopez-Denman, A., Hick, C., Wagstaff, K.M., Mackenzie, J.M., Sexton, P.M., Vasudevan, S.G., Jans, D.A., A nuclear transport inhibitor that modulates the unfolded protein response and provides in vivo protection against lethal dengue virus infection. J Infect Dis 210 (2014), 1780–1791.
52. 52 Fraser, J.E., Wang, C., Chan, K.W., Vasudevan, S.G., Jans, D.A., Novel dengue virus inhibitor 4-HPR activates ATF4 independent of protein kinase R-like endoplasmic reticulum kinase and elevates levels of eIF2alpha phosphorylation in virus infected cells. Antiviral Res 130 (2016), 1–6.
53. 53• Fink, J., Gu, F., Ling, L., Tolfvenstam, T., Olfat, F., Chin, K.C., Aw, P., George, J., Kuznetsov, V.A., Schreiber, M., Vasudevan, S.G., Hibberd, M.L., Host gene expression profiling of dengue virus infection in cell lines and patients. PLoS Negl Trop Dis, 1, 2007, e86 Comprehensive description of the gene expression profiles in DENV-infected cell lines and patient blood samples to identify biomarkers for dengue-related disease and targets for antiviral therapy.
54. 54 Fernandez-Garcia, M.D., Meertens, L., Bonazzi, M., Cossart, P., Arenzana-Seisdedos, F., Amara, A., Appraising the roles of CBLL1 and the ubiquitin/proteasome system for flavivirus entry and replication. J Virol 85 (2011), 2980–2989.
55. 55 Nag, D.K., Finley, D., A small-molecule inhibitor of deubiquitinating enzyme USP14 inhibits Dengue virus replication. Virus Res 165 (2012), 103–106.
56. 56 Choy, M.M., Zhang, S.L., Costa, V.V., Tan, H.C., Horrevorts, S., Ooi, E.E., Proteasome inhibition suppresses dengue virus egress in antibody dependent infection. PLoS Negl Trop Dis, 9, 2015, e0004058.
57. 57 Leyssen, P., Balzarini, J., De, C.E., Neyts, J., The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 79 (2005), 1943–1947.
58. 58 Schul, W., Liu, W., Xu, H.Y., Flamand, M., Vasudevan, S.G., A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis 195 (2007), 665–674.
59. 59 Malinoski, F.J., Hasty, S.E., Ussery, M.A., Dalrymple, J.M., Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys. Antiviral Res 13 (1990), 139–149.
60. 60 Wang, Q.Y., Bushell, S., Qing, M., Xu, H.Y., Bonavia, A., Nunes, S., Zhou, J., Poh, M.K., Florez de, S.P., Niyomrattanakit, P., et al. Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. J Virol 85 (2011), 6548–6556.
61. 61 Qing, M., Zou, G., Wang, Q.Y., Xu, H.Y., Dong, H., Yuan, Z., Shi, P.Y., Characterization of dengue virus resistance to brequinar in cell culture. Antimicrob Agents Chemother 54 (2010), 3686–3695.
62. 62 Hoffmann, H.H., Kunz, A., Simon, V.A., Palese, P., Shaw, M.L., Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci U S A 108 (2011), 5777–5782.
63. 63 Ariumi, Y., Multiple functions of DDX3 RNA helicase in gene regulation, tumorigenesis, and viral infection. Front Genet, 5, 2014, 423.
64. 64 Brai, A., Fazi, R., Tintori, C., Zamperini, C., Bugli, F., Sanguinetti, M., Stigliano, E., Este, J., Badia, R., Franco, S., et al. Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents. Proc Natl Acad Sci U S A 113 (2016), 5388–5393.
65. 65 Flisiak, R., Feinman, S.V., Jablkowski, M., Horban, A., Kryczka, W., Pawlowska, M., Heathcote, J.E., Mazzella, G., Vandelli, C., Nicolas-Metral, V., et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 49 (2009), 1460–1468.
66. 66 Hopkins, S., DiMassimo, B., Rusnak, P., Heuman, D., Lalezari, J., Sluder, A., Scorneaux, B., Mosier, S., Kowalczyk, P., Ribeill, Y., Baugh, J., Gallay, P., The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. J Hepatol 57 (2012), 47–54.
67. 67 Peel, M., Scribner, A., Cyclophilin inhibitors as antiviral agents. Bioorg Med Chem Lett 23 (2013), 4485–4492.
68. 68 Qing, M., Yang, F., Zhang, B., Zou, G., Robida, J.M., Yuan, Z., Tang, H., Shi, P.Y., Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein. Antimicrob Agents Chemother 53 (2009), 3226–3235.
69. 69 Kaul, A., Stauffer, S., Berger, C., Pertel, T., Schmitt, J., Kallis, S., Zayas, M., Lohmann, V., Luban, J., Bartenschlager, R., Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog, 5, 2009, e1000546.
70. 70 Xie, X., Zou, J., Wang, Q.Y., Shi, P.Y., Targeting dengue virus NS4B protein for drug discovery. Antiviral Res 118 (2015), 39–45.
71. 71 de, W.M., LaCroix, A.J., Yang, P.L., The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase. J Virol 87 (2013), 7367–7381.
72. 72 Chatel-Chaix, L., Fischl, W., Scaturro, P., Cortese, M., Kallis, S., Bartenschlager, M., Fischer, B., Bartenschlager, R., A combined genetic-proteomic approach identifies residues within dengue virus NS4B critical for interaction with ns3 and viral replication. J Virol 89 (2015), 7170–7186.
73. 73 Wang, Q.Y., Dong, H., Zou, B., Karuna, R., Wan, K.F., Zou, J., Susila, A., Yip, A., Shan, C., Yeo, K.L., et al. Discovery of dengue virus NS4B inhibitors. J Virol 89 (2015), 8233–8244.
74. 74 Chang, J., Block, T.M., Guo, J.T., Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions. Antiviral Res 99 (2013), 251–260.
75. 75 Courageot, M.P., Frenkiel, M.P., Dos Santos, C.D., Deubel, V., Despres, P., Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. J Virol 74 (2000), 564–572.
76. 76 Sayce, A.C., Alonzi, D.S., Killingbeck, S.S., Tyrrell, B.E., Hill, M.L., Caputo, A.T., Iwaki, R., Kinami, K., Ide, D., Kiappes, J.L., et al. Iminosugars inhibit dengue virus production via inhibition of ER alpha-glucosidases — not glycolipid processing enzymes. PLoS Negl Trop Dis, 10, 2016, e0004524.
77. 77 Rathore, A.P., Paradkar, P.N., Watanabe, S., Tan, K.H., Sung, C., Connolly, J.E., Low, J., Ooi, E.E., Vasudevan, S.G., Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. Antiviral Res 92 (2011), 453–460.
78. 78 Scaturro, P., Cortese, M., Chatel-Chaix, L., Fischl, W., Bartenschlager, R., dengue virus non-structural protein 1 modulates infectious particle production via interaction with the structural proteins. PLoS Pathog, 11, 2015, e1005277.
79. 79 Watanabe, S., Rathore, A.P., Sung, C., Lu, F., Khoo, Y.M., Connolly, J., Low, J., Ooi, E.E., Lee, H.S., Vasudevan, S.G., Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antiviral Res 96 (2012), 32–35.
80. 80•• Low, J.G., Sung, C., Wijaya, L., Wei, Y., Rathore, A.P., Watanabe, S., Tan, B.H., Toh, L., Chua, L.T., Hou, Y., et al. Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet Infect Dis 14 (2014), 706–715 Clinical trial evaluating the antiviral efficacy of the α-glucosidase inhbitor celgosivir in patients with dengue.
81. 81•• Watanabe, S., Chan, K.W., Dow, G., Ooi, E.E., Low, J.G., Vasudevan, S.G., Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: the search for a window for potential therapeutic efficacy. Antiviral Res 127 (2016), 10–19 A well-conducted study correlating antiviral in vivo efficacy with the time of peak viremia and showing that adjusting the dose and treatment regimen might be an effective way to overcome the problem of reduced antiviral efficacy.
82. 82• Xiao, F., Fofana, I., Thumann, C., Mailly, L., Alles, R., Robinet, E., Meyer, N., Schaeffer, M., Habersetzer, F., Doffoel, M., et al. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut 64 (2015), 483–494 An excellent example of how the combination of DAAs and HDAs might be used to achieve a synegistic antiviral effect.
83. 83 Yeo, K.L., Chen, Y.L., Xu, H.Y., Dong, H., Wang, Q.Y., Yokokawa, F., Shi, P.Y., Synergistic suppression of dengue virus replication using a combination of nucleoside analogs and nucleoside synthesis inhibitors. Antimicrob Agents Chemother 59 (2015), 2086–2093.